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Practice points
Cognitive dysfunction
 ●  Cognitive impairment is integral to progressive supranuclear palsy (PSP).
 ●  The most common impairment is a frontal dysexecutive syndrome.
 ●  PSP may also affect memory, visuospatial function and emotional recognition.
Behavioral changes
 ●  Behavioral changes can occur early in PSP.
 ●  Apathy and impulsivity commonly co-exist in people with PSP.
 ●  Emotional lability may complicate the diagnosis of depression.
Medication
 ●  Side effects of levodopa can worsen cognition in PSP.
 ●  Amantadine can be helpful to improve some cognitive aspects including alertness and motivation, but may also 
cause hallucinations, insomnia and exacerbate impulsivity.
 ●  Anticholinergic medications to reduce saliva production and for urinary symptoms should be selected carefully to 
limit cognitive side effects.
 ●  Antidepressant medication should be chosen to limit side effects and antipsychotic medications should be avoided if 
at all possible.
Educational & behavioral interventions
 ●  There is limited evidence to guide specific interventions.
 ●  An individualized management plan is likely to be the optimum approach.
 ●  Carer education and support is important in managing the cognitive and behavioral aspects of PSP.
Involving people with PSP in decisions
 ●  Optimizing communication and cognition enables people with PSP to be involved in decisions about their life and 
health.
 ●  PEG tube insertion and end of life care are two common areas for discussion.
 ●  Early discussions and better integration with palliative care services can facilitate decision-making.
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Progressive supranuclear palsy (PSP) usu-
ally affects cognitive function [1,2], despite the 
emphasis on motor deficits in the diagnostic 
criteria [3]. Cognitive impairment has a negative 
impact on the quality of life for people with PSP 
and their caregivers [4,5]. In this review we out-
line the main cognitive and behavioral changes 
encountered in PSP (see also Burrell et al. [2]) and 
consider the beneficial and detrimental effects of 
medications on cognition and behavior. We then 
present the evidence to support specific thera-
peutic intervention, and highlight the benefits 
of optimizing cognition to enable people with 
PSP to take an active role in decisions about their 
life and health.
The clinical syndrome of PSP was first 
described in 1964 [6], consisting of axial rigid-
ity, akinesia, postural instability, pseudobulbar 
palsy, slow saccadic eye movements and a supra-
nuclear gaze palsy [1,7,8]. In this review we will 
focus on the ‘Richardson syndrome’ or classi-
cal presentation of PSP. Other subtypes of PSP 
have been proposed based on differing initial 
presenting symptoms or respective review of post 
mortem cases of PSP. These subtypes include 
behavioral-onset PSP [9], Corticobasal Syndrome 
(CBS-PSP) [10], Progressive Akinesia with 
Gait Freezing (PAGF-PSP) [11,12] and Primary 
Progressive Aphasia (PPA-PSP) [13]. In addition, 
there is a substantial body of patients with neu-
ropathological evidence of PSP but who clini-
cally resembled Parkinson’s disease (PD) ante 
mortem (PSP-P, a dopamine-responsive asym-
metric syndrome [14]). The underlying pathology 
in these subtypes is difficult to predict, whereas 
the Richardson syndrome is associated with 
the pathological disease of PSP in over 90% of 
cases [15]. We, therefore, focus on the most com-
mon and typical Richardson syndrome of PSP, 
but because cognitive syndromes may overlap 
between PSP subtypes a similar approach to the 
concepts we discuss here may be applicable in 
other PSP syndromes.
The pathology of PSP is characterized by the 
accumulation of tau, a microtubule-associated 
protein. Hyperphosphorylated tau with four 
repeats of exon 10 form intracellular aggregates, 
including neurofibrillary tangles [16]. These tau 
aggregates are most densely deposited in the sub-
thalamic nucleus, substantia nigra and internal 
globus pallidus, but are also formed widely in 
cerebellar and cortical regions [17]. Tau pathol-
ogy is associated with rapid atrophy in subcor-
tical structures and the midbrain [18,19] with 
moderate atrophy in frontal cortex [16]. This 
cortical and subcortical atrophy, and associated 
neurotransmitter deficits underlie the cognitive 
deficits of PSP.
Cognitive dysfunction
The pattern of early cognitive change in PSP is 
typically summarized as a dysexecutive frontal 
syndrome [2,20,21]. This may manifest as diffi-
culty with planning and organization and can 
be readily assessed at the bedside using tests such 
as the frontal assessment battery [22], verbal flu-
ency [23] or neuropsychological tests such as Trail 
Making Test B or Brixton spatial anticipation 
test [24]. Slowness of cognitive processes, includ-
ing slow speed of processing, is characteristic of 
PSP, and has been termed bradyphrenia.
Verbal fluency can be simply measured as 
the number of words generated in 1 min either 
within a category (e.g., animals) or beginning 
with a chosen letter (e.g., p-words). The striking 
deficit of letter fluency can aid the distinction 
of PSP from idiopathic PD; we have shown that 
patients who produced fewer than seven p-words 
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Cognitive impairment is integral to the syndrome of progressive supranuclear palsy. It is 
most commonly described as a frontal dysexecutive syndrome but other impairments 
include apathy, impulsivity, visuospatial and memory functions. Cognitive dysfunction 
may be exacerbated by mood disturbance, medication and communication problems. In 
this review we advocate an individualized approach to managing cognitive impairment in 
progressive supranuclear palsy with the education of caregivers as a central component. 
Specific cognitive and behavioral treatments are complemented by treatment of mood 
disturbances, rationalizing medications and a patient-centered approach to communication. 
This aims to improve patients’ quality of life, reduce carer burden and assist people with 
progressive supranuclear palsy in decisions about their life and health, including discussions 
of feeding and end-of-life issues. 
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in a minute were much more likely to have the 
syndrome of PSP rather than PD with a positive 
predictive value of this simple test alone of 0.81 
and a negative predictive value of 0.93 [25]. Using 
the Frontal Assessment Battery and other tests 
of frontal lobe function, cognitive impairment 
is readily detectable at diagnosis but changes 
little over 12 months [24]. These findings sug-
gest that frontal cognitive impairments are well 
established early in the disease process.
Frontal executive and verbal fluency changes 
are observed in most people with PSP, but other 
cognitive functions can be affected. Many peo-
ple with PSP perform well on memory tests if 
they are given sufficient time to complete the 
test, but memory function can be affected [2] and 
may predict the level of disability better than 
other clinical features [26]. The mechanism of 
memory dysfunction may be related to frontal 
lobe pathology [21] distinct from the cholinergic 
mechanisms contributing to memory impair-
ment in Alzheimer’s disease. This hypothesis 
is consistent with the finding that cholinest-
erase inhibitors are not effective in PSP [27]. 
The domain of visuospatial function is often 
impaired in people with PSP [24,26], though 
may be overlooked in the context of other more 
striking changes.
Language deficits such as a progressive nonflu-
ent aphasia (PNFA) may be the first presentation 
of PSP [13], or can appear later in the disease 
course. Changes of PNFA include agrammatism 
and impaired comprehension of syntactically 
complex sentence structure that may limit verbal 
interaction. Furthermore, communication may 
be affected by severe hypophonia and dysarthria 
in the later stages of disease.
Recently, a severe effect of PSP on emotional 
and social cognition has been recognized [28], 
not dissimilar to patients with another neuro-
degenerative tauopathy called frontotemporal 
dementia (FTD) [29]. This change in emotion 
recognition and understanding the intentions 
of other people will exacerbate the communica-
tion and behavioral problems that significantly 
contribute to the loss of quality of life for both 
patients and their carers.
Behavioral changes
Changes in personality and behavior are often 
reported by carers, and confirmed by for-
mal assessment tools such as the Cambridge 
Behavioral Inventory [30] or the Neuropsychiatric 
Inventory [31]. Behavioral changes may occur 
early in PSP, and a behavioral or ‘frontal’ pres-
entation accounts for about 20% of all cases of 
PSP [9]. Behavioral changes are often apparent 
to families but are rarely reported by people 
with PSP themselves, a discrepancy that may be 
attributable to poor insight by patients [32].
In view of the akinesia (slowness of movement) 
in PSP, it surprises many carers and profession-
als that people with PSP are often also impul-
sive [33,34]. This may manifest as motor reckless-
ness, such as getting up to walk despite the high 
chance of falling and after repeated warnings of 
the risks involved; or of cramming food into the 
mouth even while choking. Impulsivity may be 
accompanied by inflexibility and rigid thinking. 
Families may describe this trait as stubbornness, 
selfishness or ‘bloody-mindedness’, but it reflects 
damage to the brain circuits between the frontal 
lobe and basal ganglia that regulate goal-directed 
behavior and learning [35].
In parallel with this impulsive behavior is 
an almost universal loss of motivation and apa-
thy [21] that reflects atrophy in medial frontal 
regions and insular cortex [36]. People with PSP 
tend not to initiate activities or conversations. 
This can be a source of frustration for families 
who may wish to keep their relative ‘active’ to 
preserve motor function, and can impair com-
pliance with therapeutic interventions such 
as physiotherapy or speech exercises. In other 
neurodegenerative diseases apathy has been 
associated with increased carer distress [37–39], 
more rapid disease progression [40] and poorer 
prognosis. Reports of apathetic behavior from 
carers may be due to other factors. For example 
physical disability in PSP may lead to reduced 
spontaneous movement and goal directed behav-
ior; facial hypomimia may be mistaken for lack 
of interest. Similarly, apathy may be mistaken for 
depression which may explain the marked dif-
ferences between studies in the estimated rates 
of depression in PSP, ranging from 16% [21] to 
56% [41]. However, while apathy and depression 
may coexist, they are distinct neuropsychologi-
cal constructs [42]. Many apathetic patients will 
describe their own mood as good or happy and 
assert that they do still enjoy things. This con-
trasts with the perception of a lack of motivation 
and enjoyment observed by others. In our experi-
ence depression per se is relatively uncommon in 
PSP while apathy in the absence of persistent low 
mood is present in the majority of cases.
Contributing to these behaviors, the main-
tenance and recognition of emotions may also 
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change in PSP. Emotional lability is a common 
symptom, characterized by relatively brief out-
bursts of emotion such as crying at a sad news 
story, or laughing inappropriately.
Medication
The cognitive and behavioral features outlined 
above are a consequence of the underlying neu-
ropathology in PSP, but may be exacerbated by 
treatments for the movement disorder and other 
symptoms of PSP. Levodopa and other dopa-
minergic medications are trialed in most people 
with PSP. In clear contrast to the sustained good 
response in PD dopaminergic medication is gen-
erally not effective in PSP, although may have a 
modest effect for a period of time in a minority 
of cases [43]. While the focus of most trials of 
dopaminergic therapy in PSP has been on the 
motor aspects of the disease, the cognitive effects 
of levodopa have mainly been studied in PD, 
demonstrating a nonlinear U-shaped association 
between cognitive function and dopaminergic 
medication that is influenced by the stage of dis-
ease [44,45]. While the effect (if any) of dopamin-
ergic therapy on cognition in PSP is unclear, in 
PD smaller doses may improve performance on 
tasks of cognitive set shifting, but higher doses 
‘overload’ the decision and motivation systems 
leading to impulsivity. The overload of these sys-
tems contributes to medication-related impulse 
control disorders which are relatively common in 
PD (10–15% [46]) compared with PSP, although 
there are a few case reports of dopamine-induced 
impulse control disorders in PSP [47].
Amantadine is also used in PD [48], with a 
variety of pharmacological actions, including 
NMDA antagonism [49]. Although there have 
been no clinical trials in PSP, we have often used 
amantadine in people with PSP, not only for its 
potential effect on akinetic rigidity but also to 
improve alertness, motivation, speech and bal-
ance. In a recent audit of cases, we assessed the 
effect of amantadine in 30 patients with PSP 
57% self-reported one or more benefits from 
amantadine, with more likelihood of benefit 
in younger and milder patients [Yates T et al., 
Unpublished Data]. The benefits we found were 
related to motor function in nine subjects (two 
each with improved balance, speech, stiffness, 
tremor; one with walking), seven nonspecifically 
felt better and one had markedly reduced fatigue. 
Adverse reactions to amantadine were common 
but rapidly resolved on dose reduction: two 
patients developed hallucinations or aggressive 
behavior requiring early drug cessation; three 
patients, deriving no benefit, reported mild hal-
lucinations and withdrew treatment; four devel-
oped hallucinations that resolved with reduced 
dosages and continued to benefit. Dose reduc-
tion abolished gastrointestinal disturbances in 
two cases, and insomnia and nonspecific unwell-
ness in one case each. Mild livedo reticularis may 
also occur. In a single case study amantadine 
has been associated with myoclonus in PSP [50]. 
Our approach is to start on a low dose, 100 mg 
once daily, and escalate slowly over 2 months to 
a maximum dose of 200 mg twice daily or less 
according to tolerance, having carefully briefed 
the patient and carer about side effects.
Other common medications may have signifi-
cant cognitive side effects, particularly the anti-
muscarinic medications used for incontinence, 
urgency and urinary frequency, and for other 
symptoms in PSP such as drooling (sometimes 
wrongly termed excessive saliva production). For 
example, Hyoscine is commonly used to reduce 
salivation but its systemic effects include con-
fusion, unsteadiness and complaints of ‘muzzy-
headedness’. Atropine drops used sublingually 
may be a better local treatment to reduce saliva 
production, with fewer systemic or cognitive side 
effects. There is limited evidence to support the 
use of trospium or darifenacin to treat bladder 
symptoms in people with neurodegenerative 
diseases as they cross the blood–brain bar-
rier in smaller concentrations than alterna-
tives [51,52], while noncholinergic approaches 
(e.g., Mirabegron) offer potential advantages.
There is a role for antidepressant medication 
in PSP to address mood disturbance which can 
affect cognition and behavior. However, before 
treatment of depression, one must ensure that 
the patient actually has a mood disorder. Apathy 
and facial hypomimia may falsely be interpreted 
as depression, while high scores on screening 
tests (e.g., the Beck Depression Inventory, the 
Hospital Anxiety and Depression Scale) may 
not reflect a mood disorder, but physical symp-
toms of PSP such as changes in sleep, weight, 
libido and fatigue. We suggest asking a patient 
specifically about their mood in concrete terms 
and closed questions, for example, ‘do you feel 
happy’ and ‘do you feel sad’. Although there 
is no clinical trials evidence to guide selection 
of any particular antidepressant in PSP, we 
often use citalopram for a rapid effect and low 
side effect profile. There is limited support for 
this approach from trials of selective serotonin 
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reuptake inhibitors (SSRIs) in FTD where a 
systematic review and meta-analysis found that 
antidepressant treatment results in a 15.4 point 
reduction on the Neuropsychiatric Inventory 
with the strongest evidence for SSRIs, although 
acknowledging that the evidence was derived 
from small trials [53]. Furthermore, enhancing 
serotonergic transmission with citalopram may 
have an effect on response inhibition systems 
in FTD [54]. Trazadone is also well tolerated in 
people with neurodegenerative diseases [55,56] 
while Mirtazepine can promote sleep and the 
maintenance of weight which may be of benefit 
in PSP. A single case report suggests that repeti-
tive transcranial magnetic stimulation is safe and 
may be effective for treatment-resistant depres-
sion in PSP [57]. Psychosis is rare in PSP, and 
there should be a high threshold for use of any 
antipsychotic medication given the evidence that 
long-term antipsychotic medication increases 
mortality in people with neurodegenerative 
disorders [58] and may worsen extrapyramidal 
syndromes.
There is a particular catch in the diagnosis 
of depression in PSP; the phenomenon of emo-
tional lability or emotional incontinence. This 
causes patients to suddenly, and intensely cry 
and appear distressed, often for a short period 
(less than a minute). The patient’s inner mood 
state may be very different from the external 
appearance. SSRIs are often effective for treat-
ing emotional incontinence, even in the absence 
of depression and often at lower doses than typi-
cally used to treat depression (e.g., citalopram 
10 mg once daily).
Cholinesterase inhibitors and memantine 
have been successful medications for addressing 
cholinergic deficits in Alzheimer’s disease, but 
have failed to show the same effect in PSP. An 
observational study of Rivastigmine in five peo-
ple with PSP found a small improvement after 
3–6 months in verbal fluency and backward digit 
span [59], but these results should be treated with 
caution since the study was small and unblinded, 
and there was a decline in all other cognitive 
assessments. There has been only a single rand-
omized control trial of a cholinesterase inhibitor 
in PSP [27]. This trial assessed 21 patients over 
6 weeks and found a deterioration in motor func-
tion and ability to carry out activities of daily 
living with only a small effect on memory.
Apathy is a particularly prominent cognitive 
feature of PSP and is a significant cause of patient 
morbidity [60,61] and (in other neurodegenerative 
conditions) has been linked to significant carer 
distress [62]. This makes it an attractive target 
for symptomatic therapy; however, evidence for 
particular pharmacological treatments of apathy 
in PSP is limited. In a double-blind randomized 
placebo controlled trial the GSK-3 inhibitor 
tideglusib had no effect on apathy (measured 
by the Straskiein scale) among patients with PSP 
at 52 weeks [63]. In other conditions, there is lim-
ited evidence to suggest modest effects of cho-
linesterase inhibitors improve apathetic symp-
toms in dementia [64,65], PD [66] and traumatic 
brain injury [67]. Dopamine agonists have been 
used following stroke [68] and in case reports 
amantadine [69] and selegiline [70]. The stimu-
lant modafinil showed some improvement in 
apathy in Alzheimer’s disease in a double blind 
placebo controlled trial [71] but another rand-
omized trial showed no effect [72]. Dramatic 
improvement in the symptoms of PSP (includ-
ing apathy) has been reported with the GABA 
agonist zolpidem in an individual case [73] but 
further evidence is lacking. Because apathy is not 
a single unitary construct but reflects multiple 
neuropsychological processes associated with 
disruption of a number of prefrontal and basal 
ganglia circuits [74] it is not clear which (if any) 
of these interventions are likely to be effective in 
the treatment of apathy in PSP.
Recent efforts to find a disease-modifying 
treatments for PSP have focused on disrupting 
the aggregation of hyperphosphorylated tau spe-
cies. Trials have failed to show any significant 
effect on disease progression, including cogni-
tive measures, for sodium valproate [75], davunet-
ide [76], tideglusib [63] or riluzole [15]. However, a 
series of new disease-modifying treatment trials 
are under way or planned, including immuno-
therapies. Within 5 years, the scope for disease 
modification may be much improved.
In the recent years, rasagaline, a monoam-
ine oxidase inhibitor, is suggested to have a 
disease modifying effect in idiopathic PD in 
the ADAGIO trial, although a positive result 
was seen only in the lower dose arm of the 
study [77]. A trial of rasagaline in 44 patients 
with PSP showed no effect on disease progression 
measured by the PSP Rating Scale [78].
Educational & behavioral interventions
Given the limitations of medication in managing 
cognitive and behavioral symptoms in PSP, non-
pharmacological interventions should be the first 
line of treatment. These interventions are likely 
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to have few side effects, but may require addi-
tional personnel and resources to implement, 
including education and support for caregiv-
ers. Confidence in the diagnosis, and education 
about the illness can in itself make a significant 
contribution. Understanding that personality 
and behavioral change are a result of PSP and 
not intentional callousness or selfishness can go 
a long way to reducing the problems they cause.
Limited evidence exists for nonpharmaco-
logical interventions across different neurode-
generative disorders [79]. In PSP, evidence sup-
porting general rehabilitation approaches are 
limited to a few case studies [80], and we are 
unaware of any published interventions spe-
cifically targeting cognition in PSP. A study 
providing individual assessment for 153 people 
with Alzheimer’s disease followed by a consid-
ered intervention reduced behavioral symp-
toms and carer distress with follow-up over 18 
months [81]. Interventions included cholinest-
erase inhibitors or memantine, communication 
skills education, caregiver coping skills, legal 
and finance advice, exercise and a caregiver 
guide. The study team assigned a specialist 
nurse embedded in a multidisciplinary team 
and in close partnership with caregivers. Such a 
framework is likely to be the optimum approach 
across neurodegenerative disorders, although 
crucially the interventions did not improve 
scores on cognitive tests. Despite this caveat, 
we believe that the end point of any intervention 
should be relevant to the quality of life rather 
than aiming to improve cognition and therefore 
the measurement of cognitive scores should be 
a secondary consideration when planning or 
evaluating such a study.
Translating individual interventions between 
different neurodegenerative diseases can be 
problematic. For example, disorientation 
and memory symptoms that are common in 
Alzheimer’s disease are less prominent in PSP, 
and impairment of motivation, movement and 
communication may limit people with PSP par-
ticipating in activities that may be of benefit in 
other types of dementia.
The assessment of cognition and behavior 
should include multiple sources of reference. 
Clinicians and formal assessment tools may be 
useful to identify underlying cognitive changes 
but may not easily translate into meaningful 
outcomes in the real world. Patients often lack 
insight into their own behavior and disabil-
ity; carers, despite being best placed to report 
problematic behaviors in the day-to-day setting, 
may also misinterpret the patient’s motivation or 
behavior, or project their own preconceptions or 
distress on the patient.
There is emerging evidence to guide the 
support of caregivers, although clinical tri-
als are needed. A telehealth intervention has 
been proposed to educate caregivers of people 
with PSP, although this was not particularly 
targeted at cognition and its efficacy has yet to 
be established [82]. A review of psychological 
input for family caregivers in other neurode-
generative diseases found mainly poor quality 
studies, but some evidence to support interven-
tional Behavioral Management Therapy at an 
individual level rather than in a group environ-
ment [83]. These findings further support the 
benefit of individualized, tailored interventions 
for people with PSP and their carers. In this 
review, there was no evidence to support the 
education of caregivers alone. However, rarer 
forms of dementia such as PSP might be a 
special case. Specific education has been high-
lighted as a need for carers of people with FTD 
in comparison to those caring for people with 
Alzheimer’s disease [84,85].
We propose a set of general principles for 
approaching behavioral disturbance in PSP 
(Box 1). These principles recognize the unique 
behavioral challenges in PSP while drawing on 
aspects neurodegenerative disorders more gener-
ally. Further studies are urgently needed to pro-
vide guidance in managing specific behavioral 
symptoms to guide caregivers and professionals 
in this difficult area.
Involving people with PSP in decisions
An important goal of maximizing cognition 
and communication is to involve people with 
PSP in decisions about their life and healthcare. 
To demonstrate the importance of improving 
cognition in PSP, we will discuss two areas for 
decision-making with which medical teams are 
often involved: inserting a percutaneous endo-
scopic gastrostomy (PEG) feeding tube; and end 
of life decisions.
Considering a PEG in people with PSP is 
common since swallowing problems usually 
develop during the course of PSP, leading to 
a risk of aspiration pneumonia, weight loss, 
unpleasant choking episodes and lengthy meal-
times. Although a PEG tube does not prevent 
aspiration pneumonia, it can have benefits in 
terms of maintaining nutrition and comfort and 
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does not preclude eating for pleasure. There is a 
lack of evidence to help with the timing of PEG 
placement, although studies in motor neuron 
disease support early placement since waiting 
until there is significant weight loss, malnu-
trition and dysphagia increases postprocedure 
mortality [86], though practice varies between 
centers on optimal timing for PEG placement. 
Many people with PSP do not wish to have a 
PEG tube for cosmetic reasons, concerns about 
the insertion procedure or because they do not 
like the idea of ‘artificial feeding’. Patients may 
also misunderstand the palliative role of PEG, 
rather than prolonging life per se.
Similarly, discussions around end of life care 
are sensitive and often very personal. These 
include decisions about where to die, whether 
to be admitted to hospital to treat infections 
and resuscitation status. Poor communication 
between neurologists and palliative care teams 
may hinder such discussions [87] and a recent 
survey across the UK highlights the variability 
between regions in the integration of neurology 
and palliative care services in PSP and other 
neurological disorders [88]. We advocate early 
discussions about palliative care issues and early 
involvement of palliative care teams to assist with 
advance care planning in PSP. It may not be 
comfortable for the clinician to talk about death, 
fear of death, the processes of dying, and guilt 
about surviving carers, but patients may be pre-
occupied and worried by these issues. Clarifying 
their concerns reduces the risk of making false 
assumptions and can enable reassurance and 
practical measures to be put in place.
In the early years of PSP around the time of 
diagnosis, the majority of people with PSP will 
have the communication and cognitive abilities 
to discuss PEG placement and end of life deci-
sions. Later on in the disease this legal process 
may need facilitating by a careful assessment of 
capacity, maximizing cognitive function and 
optimizing communication.
To properly involve people with PSP and 
impaired cognition in these important decisions 
takes time and patience. A discussion that may 
take a few minutes with a healthy person can 
take half an hour in someone with PSP. Our 
experience is that this is time well spent, and 
a clearly documented discussion can pave the 
way for clear decision-making in moments of 
crisis. There is some evidence that Lee Silverman 
exercises, designed to address hypophonia in 
idiopathic PD, can be of benefit in promoting 
communication in PSP [89]. Further specific 
guidance for improving communication in 
PSP is greatly needed but currently lacking [90]. 
In addition to the medical and nonmedical 
measures to improve cognition outlined in 
preceding sections, the environment in which 
a decision is made can be optimized to assist 
decision-making [91].
Supporting these decisions within a legal 
framework can add an additional level of pro-
tection for an individual’s wishes [92]. In the 
UK the Mental Capacity Act 2005 provides 
the framework within which these decisions 
are made, although the implementation of the 
Act by neurologists is variable [93]. The Mental 
Capacity Act makes provision to appoint a 
lasting power of attorney, whereby a person of 
sound mind can nominate someone to take on 
financial and medical decisions if they become 
incapacitated at a later date. In addition, an 
individual can make more specific statements 
to refuse care, given a certain set of circum-
stances written down as advanced statements, 
or more formal legal documents called advance 
directives.
Future perspective
In 5–10 year’s time we hope that cognitive dys-
function in PSP will be recognized as a core 
feature in revised diagnostic guidelines. We 
would like to see the standard evaluation of 
a person with PSP to include a formal assess-
ment of cognition, and the standard treatment 
to begin with formalized education of carers 
about cognitive issues. We expect that increased 
awareness of the Mental Health Act and the 
Box 1. Principles of behavioral management in progressive supranuclear palsy.
 ●  Gather information on behavior from multiple sources, for example the patient, family, professional 
caregivers, therapists
 ●  Specific education for caregivers about the cognitive and behavioral spectrum of progressive 
supranuclear palsy, particularly apathy, impulsivity and emotional lability
 ●  Address systemic causes of behavioral change, for example infection, constipation, pain
 ●  Reduce medication where possible that may cause cognitive impairment, drowsiness or hallucinations
 ●  Low-dose selective serotonin reuptake inhibitor may help to treat emotional lability
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growth of neuropalliative care will lead to 
better integration between neurologists and 
palliative care physicians enabling better opti-
mization of cognition and communication to 
facilitate advanced care planning and avoiding 
crisis situations.
Conclusion
In conclusion, the Richardson syndrome of PSP 
is associated with many cognitive and behavio-
ral changes, including apathy, impulsivity and 
a frontal dysexecutive syndrome. Cognition can 
be worsened by side effects of common medica-
tions. There is little clinical trials’ evidence to 
guide the management of these symptoms, but 
here we set out the rationale and strategies for 
treating mood disturbance, educating patients 
and their caregivers, and the benefits of involving 
people with PSP in decision-making about their 
life and health.
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